(NUVB) Nuvation Bio - Ratings and Ratios
Oncology Pipeline Drug Candidates
NUVB EPS (Earnings per Share)
NUVB Revenue
Description: NUVB Nuvation Bio
Nuvation Bio (NUVB) is a U.S.-based biotech firm concentrating on the development of novel therapeutics for rare diseases, leveraging proprietary gene‑editing and protein‑modulation platforms. The company’s strategic focus is on advancing a pipeline of pre‑clinical and early‑stage clinical candidates targeting high‑unmet‑need indications, positioning it to capture niche market share if regulatory milestones are achieved.
Financially, the firm operates with a market capitalization under $1 billion and exhibits negative equity returns, reflecting substantial R&D outlays relative to revenue. Cash balances are modest, resulting in a burn rate that necessitates periodic equity raises or partnership financing. The balance sheet shows limited debt, indicating reliance on equity markets for capital. Gross margin is not applicable due to the pre‑revenue nature of the business, and operating expenses are dominated by research, clinical trial costs, and administrative overhead.
The primary economic drivers are milestone payments and licensing revenues from collaborations with larger pharmaceutical partners, as well as potential product commercialization upon successful FDA approval. The pipeline includes at least two candidates in IND‑enabling studies, each targeting orphan indications with market sizes estimated in the low‑hundreds of millions. Successful trial outcomes would unlock significant upside through out‑licensing or direct market entry, while also enhancing the company’s credibility for future financing.
External factors influencing valuation include the biotech sector’s capital environment, regulatory risk, and competitive pressure from other firms pursuing similar mechanisms of action. Market sentiment is sensitive to trial data releases and partnership announcements; any delay or negative result can materially depress share price, whereas positive data can trigger rapid re‑rating by analysts.
NUVB Stock Overview
| Market Cap in USD | 1,078m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-08-24 |
NUVB Stock Ratings
| Growth Rating | 12.2% |
| Fundamental | 29.9% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -10.3% |
| Analyst Rating | 4.57 of 5 |
NUVB Dividends
Currently no dividends paidNUVB Growth Ratios
| Growth Correlation 3m | 93.8% |
| Growth Correlation 12m | -15.4% |
| Growth Correlation 5y | -66% |
| CAGR 5y | 17.40% |
| CAGR/Max DD 3y | 0.28 |
| CAGR/Mean DD 3y | 0.54 |
| Sharpe Ratio 12m | -0.05 |
| Alpha | 0.13 |
| Beta | 0.693 |
| Volatility | 76.33% |
| Current Volume | 6346.2k |
| Average Volume 20d | 5097.3k |
| Stop Loss | 3 (-8.3%) |
| Signal | 1.21 |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-202.9m TTM) > 0 and > 6% of Revenue (6% = 861.3k TTM) |
| FCFTA -0.20 (>2.0%) and ΔFCFTA -8.73pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 3879 % (prev 27.3k%; Δ -23.4kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.26 (>3.0%) and CFO -168.2m > Net Income -202.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 9.39 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (340.7m) change vs 12m ago 39.23% (target <= -2.0% for YES) |
| Gross Margin 27.54% (prev 10.39%; Δ 17.15pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 2.31% (prev 0.33%; Δ 1.98pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -219.2 (EBITDA TTM -149.2m / Interest Expense TTM 684.0k) >= 6 (WARN >= 3) |
Altman Z'' 0.30
| (A) 0.86 = (Total Current Assets 623.2m - Total Current Liabilities 66.4m) / Total Assets 647.2m |
| (B) -1.58 = Retained Earnings (Balance) -1.02b / Total Assets 647.2m |
| warn (B) unusual magnitude: -1.58 — check mapping/units |
| (C) -0.24 = EBIT TTM -149.9m / Avg Total Assets 621.0m |
| (D) 1.36 = Book Value of Equity 372.9m / Total Liabilities 274.3m |
| Total Rating: 0.30 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 29.92
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield -24.75% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.15 = 2.49 |
| 5. Debt/Ebitda -0.38 = -2.50 |
| 6. ROIC - WACC (= -40.90)% = -12.50 |
| 7. RoE -46.14% = -2.50 |
| 8. Rev. Trend 88.73% = 6.65 |
| 9. EPS Trend -54.49% = -2.72 |
What is the price of NUVB shares?
Over the past week, the price has changed by -2.39%, over one month by +12.76%, over three months by +75.81% and over the past year by +6.51%.
Is Nuvation Bio a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NUVB is around 3.04 USD . This means that NUVB is currently overvalued and has a potential downside of -7.03%.
Is NUVB a buy, sell or hold?
- Strong Buy: 4
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the NUVB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7.5 | 129.4% |
| Analysts Target Price | 7.5 | 129.4% |
| ValueRay Target Price | 3.4 | 3.1% |
Last update: 2025-09-05 04:54
NUVB Fundamental Data Overview
CCE Cash And Equivalents = 607.7m USD (Cash And Short Term Investments, last quarter)
P/S = 75.1069
P/B = 2.8912
Beta = 1.352
Revenue TTM = 14.4m USD
EBIT TTM = -149.9m USD
EBITDA TTM = -149.2m USD
Long Term Debt = 47.0m USD (from longTermDebt, last quarter)
Short Term Debt = 10.2m USD (from shortTermDebt, last quarter)
Debt = 57.2m USD (Calculated: Short Term 10.2m + Long Term 47.0m)
Net Debt = -44.6m USD (from netDebt column, last quarter)
Enterprise Value = 527.6m USD (1.08b + Debt 57.2m - CCE 607.7m)
Interest Coverage Ratio = -219.2 (Ebit TTM -149.9m / Interest Expense TTM 684.0k)
FCF Yield = -24.75% (FCF TTM -130.6m / Enterprise Value 527.6m)
FCF Margin = -909.6% (FCF TTM -130.6m / Revenue TTM 14.4m)
Net Margin = -1413 % (Net Income TTM -202.9m / Revenue TTM 14.4m)
Gross Margin = 27.54% ((Revenue TTM 14.4m - Cost of Revenue TTM 10.4m) / Revenue TTM)
Tobins Q-Ratio = 1.41 (Enterprise Value 527.6m / Book Value Of Equity 372.9m)
Interest Expense / Debt = 0.74% (Interest Expense 421.0k / Debt 57.2m)
Taxrate = 21.0% (US default)
NOPAT = -149.9m (EBIT -149.9m, no tax applied on loss)
Current Ratio = 9.39 (Total Current Assets 623.2m / Total Current Liabilities 66.4m)
Debt / Equity = 0.15 (Debt 57.2m / last Quarter total Stockholder Equity 372.9m)
Debt / EBITDA = -0.38 (Net Debt -44.6m / EBITDA -149.2m)
Debt / FCF = -0.44 (Debt 57.2m / FCF TTM -130.6m)
Total Stockholder Equity = 439.7m (last 4 quarters mean)
RoA = -31.35% (Net Income -202.9m, Total Assets 647.2m )
RoE = -46.14% (Net Income TTM -202.9m / Total Stockholder Equity 439.7m)
RoCE = -30.80% (Ebit -149.9m / (Equity 439.7m + L.T.Debt 47.0m))
RoIC = -32.74% (NOPAT -149.9m / Invested Capital 458.0m)
WACC = 8.17% (E(1.08b)/V(1.14b) * Re(8.57%)) + (D(57.2m)/V(1.14b) * Rd(0.74%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 4.13%
Discount Rate = 8.57% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -130.6m)
EPS Correlation: -54.49 | EPS CAGR: -46.62% | SUE: 0.0 | # QB: 0
Revenue Correlation: 88.73 | Revenue CAGR: 575.6%
Additional Sources for NUVB Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle